Stock Price, News, Quote and Profile of ROIVANT SCIENCES LTD(NASDAQ:ROIV) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ROIVANT SCIENCES LTD

NASDAQ:ROIV (7/26/2024, 7:00:01 PM)

After market: 10.85 +0.05 (+0.46%)

10.8

+0.06 (+0.56%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustry

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%

Sales Q2Q%

CRS

6 Month4.15%

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap7.98B

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor in development across several IgG-mediated autoimmune indications; and brepocitinib, a TYK2/JAK1 inhibitor in late stage development for dermatomyositis, non-infectious uveitis, and other autoimmune conditions, in addition to other clinical-stage molecules. The company advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.